Connecting the Oncology Community in Oklahoma

OSCO serves as the hub for oncology-related news and advances in Oklahoma. Our organization is made up of clinics and healthcare professionals working together to safeguard the rights of patients and to maintain high medical and ethical standards in the industry.

News

New life-changing survival data for women with HR+/HER2- metastatic breast cance

Novartis is pleased to share new study results for KISQALI® (ribociclib), which now include overall survival (OS) data that no other CDK 4/6 inhibitor has yet reported: statistically significant OS in in first-line postmenopausal patients with an aromatase inhibitor.1 MONALEESA-2 was a dedicated first-line trial of KISQALI + letrozole vs placebo + letrozole in postmenopausal patients […]

Read More...

Takeda announces FDA approval for EXKIVITY™ (mobocertinib)

Takeda has announced that the US Food and Drug Administration (FDA) has approved EXKIVITY™ (mobocertinib), the first oral therapy to target epidermal growth factor receptor (EGFR) exon 20 insertion mutations in metastatic non-small cell lung cancer (NSCLC).1 EXKIVITY is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic NSCLC […]

Read More...

Merck’s WELIREG™ (belzutifan) Receives FDA Approval

Merck has informed OSCO that WELIREG™ (belzutifan) 40-mg tablets has received FDA approval. WELIREG is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. SELECTED SAFETY INFORMATION WARNING: EMBRYO-FETAL […]

Read More...

Upcoming Events

Join the Oklahoma Society of Clinical Oncology, Inc. for our fall meeting on November 6, 2021, ASCO Direct™, an officially licensed program of the American Society of Clinical Oncology®.  This virtual meeting will break down the most clinically relevant abstracts from ASCO’s annual symposium, allowing attendees to engage with the latest strategies in oncology education.  All exhibitors will have access to the full meeting application and will be able to view all the virtual sessions.  Details of the virtual meeting are:

Learn More »

Become a Sponsor

Your company can sponsor OSCO and the work we do by becoming a corporate member today! For more information or to sign up, contact Kathy Musson, OSCO Executive Director at kmussonokc@gmail.com or by phone at 405-850-8334.

See More »

Who We Are

Who We Are

The Oklahoma Society of Clinical Oncology (OSCO) is Oklahoma’s only professional organization that represents all those in oncology. Our membership works to advance the sciences of hematology and oncology and its sub-specialties, and to improve services to the public by studying the socio-economic aspects of the practice of our members.

Learn More »